2022
Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors
Chawla N, Sayegh N, Tripathi N, Govindarajan A, Zengin Z, Phillip E, Dizman N, Meza L, Muddasani R, Chehrazi-Raffle A, Malhotra J, Hsu J, Agarwal N, Pal S, Tripathi A. Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer 2022, 21: 69-75. PMID: 36509613, DOI: 10.1016/j.clgc.2022.11.007.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCarcinoma, Transitional CellFemaleGenomicsHumansImmune Checkpoint InhibitorsPrognosisRetrospective StudiesUrinary Bladder NeoplasmsConceptsProgression-free survivalOverall response rateTumor mutational burdenOverall survivalWorse OSPrimary diseaseMultivariate analysisMedian progression-free survivalImmune checkpoint inhibitor therapyInferior progression-free survivalPromoter mutationsWorse progression-free survivalCheckpoint inhibitor therapyMedian overall survivalImmune checkpoint inhibitorsTertiary cancer centerClinical prognostic factorsPrimary tumor siteTERT promoter mutationsCheckpoint inhibitorsInhibitor therapyLaboratory parametersPrognostic factorsCancer CenterFemale sex
2021
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma
Zengin Z, Chehrazi-Raffle A, Salgia N, Muddasani R, Ali S, Meza L, Pal S. Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma. Urologic Oncology Seminars And Original Investigations 2021, 40: 25-36. PMID: 34840077, DOI: 10.1016/j.urolonc.2021.10.003.Peer-Reviewed Original ResearchMeSH KeywordsFemaleHumansMaleProtein Kinase InhibitorsReceptor, Fibroblast Growth Factor, Type 3Urinary Bladder NeoplasmsConceptsImmune checkpoint inhibitorsUrothelial carcinomaCheckpoint inhibitorsTargeted therapyLower tract diseaseMultiple disease stagesMetastatic urothelial carcinomaOverall response rateAntibody-drug conjugatesGrowth factor receptor familyFGFR3 inhibitionUC tumorsChemotherapy regimensUpper tractOngoing trialsDisease stageTract diseaseTreatment paradigmFactor receptor familyHigh incidenceActionable mutationsFGFR1-4FGFR3 inhibitorsSmall molecule inhibitorsFGFR3 mutationsCabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma
Meza L, Malhotra J, Favorito C, Pal S. Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma. Future Oncology 2021, 18: 21-33. PMID: 34766841, DOI: 10.2217/fon-2021-0570.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMetastatic renal cell carcinomaMetastatic urothelial carcinomaTargeted therapyTreatment of metastatic RCCMetastatic renal cellNonresponders to monotherapyRenal cell carcinomaIncrease clinical responsesImmunotherapy combinationsMetastatic RCCUrothelial carcinomaClinical responseCell carcinomaProgressive diseaseIO agentsTreatment optionsRenal cellsImmunotherapyQuality of lifeCabozantinibMonotherapyCarcinomaNovel approachesNonrespondersTherapyLearning from BISCAY: The future of biomarker-based trial design in bladder cancer
Meza L, Salgia N, Patel K, Pal S. Learning from BISCAY: The future of biomarker-based trial design in bladder cancer. Cancer Cell 2021, 39: 910-912. PMID: 34256907, DOI: 10.1016/j.ccell.2021.06.011.Commentaries, Editorials and LettersMeSH KeywordsBiomarkersCarcinoma, Transitional CellForecastingHumansImmunotherapyUrinary Bladder NeoplasmsChemoimmunotherapy in urothelial cancer: concurrent or sequential?
Zengin Z, Meza L, Pal S, Grivas P. Chemoimmunotherapy in urothelial cancer: concurrent or sequential? The Lancet Oncology 2021, 22: 894-896. PMID: 34051179, DOI: 10.1016/s1470-2045(21)00284-9.Commentaries, Editorials and LettersBiomarker approach harnessed in trials of personalized medicine for bladder cancer
Dizman N, Meza L, Pal SK. Biomarker approach harnessed in trials of personalized medicine for bladder cancer. Nature Medicine 2021, 27: 761-763. PMID: 33941920, DOI: 10.1038/s41591-021-01300-1.Commentaries, Editorials and Letters